Healthcare Industry News: Wright Medical Group
News Release - January 12, 2011
Wright Medical Group, Inc. Announces Launch of DARCO(R) Foot & Ankle Plating Line in Japan
New Foot & Ankle Product Approval Expands Wright’s Extremity Portfolio in JapanARLINGTON, Tenn.--(Healthcare Sales & Marketing Network)-- Wright Medical Group, Inc. (NASDAQ:WMGI ), a global orthopaedic medical device company, today announced the launch of the DARCO® Foot & Ankle Plating System in Japan. The DARCO® Plating System consists of over 40 different locked plates specifically designed to meet the needs of foot and ankle surgeons. Wright has been selling the DARCO® Plating System in the United States and other key global markets since 2007.
Karen L. Harris-Coleman, Wright’s Sr. V.P. International Sales & Marketing –Japan, Australia, Asia, Latin America, commented, “The regulatory approval and launch of the DARCO® Plating System is an important extension of Wright’s strategy to be the global leader in foot and ankle surgical products. The DARCO® plating line is the first indication-specific fixation product for reconstructive foot and ankle surgery in Japan, and builds on Wright’s powerful Japanese extremity portfolio including the MICRONAIL® system for distal radius fractures. We are committed to bringing key technologies and products to this important market and look forward to introducing our other specialized foot and ankle products in the future.”
About Wright
Wright Medical Group, Inc. is a global orthopaedic medical device company and a leading provider of surgical solutions for the foot and ankle market. The Company specializes in the design, manufacture and marketing of devices and biologic products for extremity, hip and knee repair and reconstruction. The Company has been in business for 60 years and markets its products in over 60 countries worldwide. For more information about Wright Medical, visit the Company’s website at www.wmt.com.
This press release contains “forward-looking statements” as defined under U.S. federal securities laws. These statements reflect management’s current knowledge, assumptions, beliefs, estimates, and expectations and express management’s current views of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Such risks and uncertainties include the impact of Wright's settlement of the federal investigation into Wright's consulting arrangements with orthopaedic surgeons relating to its hip and knee products in the United States, including Wright's compliance with a Deferred Prosecution Agreement through September 2011 and a Corporate Integrity Agreement through September 2015, and those risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009, under the heading, “Risk Factors” and in Item 1A of Part II of our 10-Qs filed during 2010). Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date of this press release, and we undertake no obligation to update such statements after this date.
Source: Wright Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
